Arch Venture Partners, a Chicago, IL-based venture capital firm, closed Arch Venture Fund XII, at $2.975 billion.
The fund will invest in the creation, development and funding of early stage biotechnology companies with potential to solve some of the biggest health challenges in areas including infectious disease, mental health, immunology, oncology, neurology, age-related diseases, manufacturing, clinical trials, genomic and biological tools, data sciences, and ways to reimagine diagnostics and therapies.
Arch’s Managing Directors include:
- Robert Nelsen
- Keith Crandell
- Kristina Borow
- Mark McDonnell
- Steve Gillis
- Paul Berns